Dianthus Therapeutics, Inc. /DE/ Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Dianthus Therapeutics, Inc. /DE/ quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2017 to Q2 2024.
  • Dianthus Therapeutics, Inc. /DE/ Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $3.1M, a 571% increase year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $7.04M.
  • Dianthus Therapeutics, Inc. /DE/ annual Share-based Payment Arrangement, Expense for 2023 was $2.9M, a 91% increase from 2022.
  • Dianthus Therapeutics, Inc. /DE/ annual Share-based Payment Arrangement, Expense for 2022 was $1.52M, a 2310% increase from 2021.
  • Dianthus Therapeutics, Inc. /DE/ annual Share-based Payment Arrangement, Expense for 2021 was $63K, a 99.4% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $7.04M $3.1M +$2.64M +571% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $4.4M $2.04M +$1.5M +282% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $2.9M $726K +$3.62M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$719K $1.18M +$518K +78.4% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$1.24M $462K -$1.38M -75% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $146K $533K -$1.37M -72% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $1.52M -$2.89M +$5.17M +64.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$3.65M $661K -$3.14M -82.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$513K $1.85M -$289K -13.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$224K $1.91M -$287K -13.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $63K -$8.06M -$10.4M -446% Oct 1, 2021 Dec 31, 2021 8-K 2023-12-21
Q3 2021 $10.5M $3.8M +$1.43M +60.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $9.02M $2.13M -$370K -14.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $9.39M $2.19M -$548K -20% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $9.94M $2.33M +$269K +13% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-08
Q3 2020 $9.67M $2.37M -$396K -14.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $10.1M $2.5M -$96K -3.69% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $10.2M $2.74M +$163K +6.33% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $10M $2.06M -$489K -19.2% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-03
Q3 2019 $10.5M $2.76M -$914K -24.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $11.4M $2.6M -$451K -14.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $11.9M $2.58M +$1.15M +80.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $10.7M $2.55M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-03
Q3 2018 $3.68M +$3.11M +551% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 $3.05M +$2.44M +403% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $1.43M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q3 2017 $565K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $607K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.